Blood pressure targets for patients with diabetes or kidney disease

Current Hypertension Reports

Volumn 13, Issue 6, 2011, Pages 452-455

  Flynn, Colleen ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Blood pressure goals; CKD; Clinical trials; Guidelines; Hypertension; Kidney disease; Nephropathy; Outcomes; Proteinuria; Renal disease; Stroke risk

Indexed keywords

GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETIC PATIENT; DYSLIPIDEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RISK ASSESSMENT; RISK REDUCTION;

BLOOD PRESSURE; DIABETES MELLITUS; DISEASE PROGRESSION; GOALS; HUMANS; HYPERTENSION; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; RISK ASSESSMENT;

EID: 81255178654     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0228-5     Document Type: Article

References (27)

1. JB Buse HN Ginsberg GL Bakris NG Clark F Costa R Eckel V Fonseca HC Gerstein S Grundy RW Nesto MP Pignone J Plutzky D Porte R Redberg KF Stitzel NJ Stone 2007 Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Circulation 115 114 126 17192512 10.1161/CIRCULATIONAHA.106.179294 (Pubitemid 46058619)
2. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34 Suppl 1:S11-61.
3. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr DW Jones BJ Materson S Oparil JT Wright Jr EJ Roccella 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 1252 14656957 10.1161/01.HYP.0000107251. 49515.c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D (Pubitemid 37553153)
4. G Mancia G De Backer A Dominiczak R Cifkova R Fagard G Germano G Grassi AM Heagerty SE Kjeldsen S Laurent K Narkiewicz L Ruilope A Rynkiewicz RE Schmieder HA Boudier A Zanchetti A Vahanian J Camm CR De V Dean K Dickstein G Filippatos C Funck-Brentano I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano S Erdine W Kiowski E Agabiti-Rosei E Ambrosioni LH Lindholm M Viigimaa S Adamopoulos E Agabiti-Rosei E Ambrosioni V Bertomeu D Clement S Erdine C Farsang D Gaita G Lip JM Mallion AJ Manolis PM Nilsson E O'Brien P Ponikowski J Redon F Ruschitzka J Tamargo 2007 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 1187 17563527 10.1097/HJH.0b013e3281fc975a 1:CAS:528:DC%2BD2sXmtlWnsr0%3D (Pubitemid 46924065)
5. JA Staessen Y Li L Thijs JG Wang 2005 Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials Hypertens Res 28 385 407 16156503 10.1291/hypres.28.385 (Pubitemid 41014801)
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13.
7. L Hansson A Zanchetti SG Carruthers B Dahlof D Elmfeldt S Julius J Menard KH Rahn H Wedel S Westerling 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1755 1762 9635947 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D (Pubitemid 28269185)
8. RO Estacio BW Jeffers N Gifford RW Schrier 2000 Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 B54 B64 10860192
9. WC Cushman GW Evans RP Byington DC Goff Jr RH Grimm Jr JA Cutler, et al. 2010 Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 1575 1585 20228401 10.1056/NEJMoa1001286 This report of the main BP results of the ACCORD trial details the benefits of lower BP levels, along with the outcome results and adverse events
10. A Patel S MacMahon J Chalmers B Neal M Woodward L Billot S Harrap N Poulter M Marre M Cooper P Glasziou DE Grobbee P Hamet S Heller LS Liu G Mancia CE Mogensen CY Pan A Rodgers B Williams 2007 Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 829 840 17765963 10.1016/S0140-6736(07)61303-8 1:CAS:528:DC%2BD2sXhtVWjs7zO (Pubitemid 47362321)
11. R Kalaitzidis GL Bakris 2009 Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich) 11 345 347 10.1111/j.1751-7176.2009.00143.x This article presents a detailed systematic review of the evidence on cardiovascular and kidney disease progression and the role of BP goals in outcome
12. RM Cooper-DeHoff Y Gong EM Handberg AA Bavry SJ Denardo GL Bakris CJ Pepine 2010 Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 304 61 68 20606150 10.1001/jama.2010.884 1:CAS:528:DC%2BC3cXovVSjurY%3D
13. P Sleight J Redon P Verdecchia G Mancia P Gao R Fagard H Schumacher M Weber M Bohm B Williams J Pogue T Koon S Yusuf 2009 Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 27 1360 1369 19506526 10.1097/HJH.0b013e32832d7370 1:CAS:528:DC%2BD1MXnsVyis7g%3D
14. T Ninomiya V Perkovic M Gallagher M Jardine A Cass H Arima C Anderson B Neal M Woodward T Omae S MacMahon J Chalmers 2008 Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial Kidney Int 73 963 970 18272959 10.1038/ki.2008.5 1:STN:280: DC%2BD1c3itFCgsw%3D%3D (Pubitemid 351458323)
15. A Upadhyay A Earley SM Haynes K Uhlig 2011 Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Ann Intern Med 154 541 548 21403055 This systematic review presents in detail all three major trials on CKD outcomes and blood pressure levels. The conclusions summarized in this overview will be reflected in upcoming guidelines
16. JC Peterson S Adler JM Burkart T Greene LA Hebert LG Hunsicker AJ King S Klahr SG Massry JL Seifter 1995 Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 754 762 7574193 1:STN:280:DyaK28%2FjtVOntw%3D%3D
17. MJ Sarnak T Greene X Wang G Beck JW Kusek AJ Collins AS Levey 2005 The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study Ann Intern Med 142 342 351 15738453 (Pubitemid 40293407)
18. JT Wright Jr G Bakris T Greene LY Agodoa LJ Appel J Charleston, et al. 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2421 2431 12435255 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D (Pubitemid 35340538)
19. LJ Appel JT Wright Jr T Greene JW Kusek JB Lewis X Wang, et al. 2008 Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans Arch Intern Med 168 832 839 18443258 10.1001/archinte.168.8.832 1:CAS:528:DC%2BD1cXmtFSrsLY%3D This article reports the culmination of the longest follow-up, 10 years, on CKD progression in largely nonproteinuric(i.e., <300 mg/d) patients with GFR starting in the 40s. There was no benefit of a lower BP level in these people unless they had more than 300 mg/day of proteinuria. (Pubitemid 351620085)
20. LJ Appel JT Wright Jr T Greene LY Agodoa BC Astor GL Bakris, et al. 2010 Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 918 929 20818902 10.1056/NEJMoa0910975 1:CAS:528:DC%2BC3cXhtFWjsbzN
21. BM Brenner ME Cooper D de Zeeuw WF Keane WE Mitch HH Parving G Remuzzi SM Snapinn Z Zhang S Shahinfar RENAAL Study Investigators 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 11565518 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D
22. EJ Lewis LG Hunsicker WR Clarke T Berl MA Pohl JB Lewis E Ritz RC Atkins R Rohde I Raz Collaborative Study Group 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 11565517 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D
23. EJ Lewis LG Hunsicker RP Bain RD Rohde 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1456 1462 8413456 10.1056/NEJM199311113292004 1:STN:280:DyaK2c%2FhvFKitQ%3D%3D (Pubitemid 23335891)
24. FF Hou X Zhang GH Zhang D Xie PY Chen WR Zhang JP Jiang M Liang GB Wang ZR Liu RW Geng 2006 Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 131 140 16407508 10.1056/NEJMoa053107 1:CAS:528:DC%2BD28XisFWitQ%3D%3D (Pubitemid 43076710)
25. P Ruggenenti A Perna G Loriga M Ganeva B Ene-Iordache M Turturro M Lesti E Perticucci IN Chakarski D Leonardis G Garini A Sessa C Basile M Alpa R Scanziani G Sorba C Zoccali G Remuzzi REIN-2 Study Group 2005 Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial Lancet 365 939 946 15766995 10.1016/S0140-6736(05)71082-5 (Pubitemid 41071427)
26. GL Bakris PA Sarafidis MR Weir B Dahlöf B Pitt K Jamerson EJ Velazquez L Staikos-Byrne RY Kelly V Shi YT Chiang MA Weber ACCOMPLISH Trial Investigators 2010 Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 1173 1181 20170948 10.1016/S0140-6736(09)62100-0 1:CAS:528:DC%2BC3cXktlGitr8%3D
27. GL Bakris JB Copley N Vicknair R Sadler S Leurgans 1996 Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney Int 50 1641 1650 8914031 10.1038/ki.1996.480 1:CAS:528:DyaK28Xms1ylsLk%3D (Pubitemid 26364270)